Signals
Every pharma-relevant, de-duplicated event surfaced so far, primary source first. Client-scoped signals are never shown here.
ASTRAZENECA PLC · 6-K filed 2026-07-27
ASTRAZENECA PLC · UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA
ASTRAZENECA PLC · SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS
ASTRAZENECA PLC · ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER
ASTRAZENECA PLC · ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR
ASTRAZENECA PLC · UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
CompaniesEli Lilly and CompanyAssetsMounjaroZepboundEbglyssJaypircaRetatrutideOrna Therapeutics, Inc.Ajax Therapeutics, Inc.Centessa Pharmaceuticals plc.Kelonia Therapeutics, Inc.AtaiBeckley, Inc.OmvohFoundayoRetevmoVERVE-102Diseasesatopic dermatitischronic lymphocytic leukemiaobesityobstructive sleep apneaknee osteoarthritis paintype 2 diabetesulcerative colitispancreatic cancertreatment-resistant depression
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
CompaniesEli Lilly and Company